Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.
Masaki YoshidaMasayuki TakedaMomokazu GotohOsamu YokoyamaHidehiro KakizakiSatoru TakahashiNaoya MasumoriShinji NagaiKazuyoshi MinemuraPublished in: Neurourology and urodynamics (2021)
Vibegron was suggested to be similarly effective in patients ≥65 and <65 years and to have minimal influence on cardiovascular parameters.
Keyphrases
- placebo controlled
- double blind
- end stage renal disease
- clinical trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- study protocol
- phase ii
- phase iii
- physical activity
- open label
- randomized controlled trial
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes